Lewis T. "Rusty" Williams, M.D., Ph.D.
Founder, President and CEO
Dr. Williams founded the company in December 2001 and has served as a member of our board of directors since January 2002, as our President and Chief Executive Officer since August 2011, and as our Executive Chairman from July 2003 to January 2012. Previously, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. He also served on Chiron’s board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the boards of directors of COR Therapeutics, Inc. and Beckman Coulter, Inc., each of which was a public company. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.
Julie Hambleton, M.D.
Senior Vice President and Chief Medical Officer
Dr. Hambleton has served as our Senior Vice President and Chief Medical Officer since December 2012. From April 2010 to December 2012, Dr. Hambleton served as Vice President, Clinical Development, at Clovis Oncology, Inc., a public biopharmaceutical company. From 2003 to April 2010, Dr. Hambleton served at Genentech, Inc., a biotechnology company acquired by Hoffman-LaRoche AG, in positions of increasing responsibility, most recently as Group Medical Director, Global Clinical Development from July 2009 to April 2010. Prior to 2003, Dr. Hambleton served for 10 years in academic positions in the Division of Hematology/Oncology at the University of California, San Francisco, most recently as Associate Professor of Clinical Medicine. Dr. Hambleton received a B.S. from Duke University and an M.D. from Case Western Reserve University School of Medicine. She is Board Certified in Hematology and Internal Medicine.
Senior Vice President and Chief Financial Officer
Mr. Belsky has served as our Vice President and Chief Financial Officer since October 2013. From October 2009 to October 2013 he served as our Vice President, Finance. From December 2006 to October 2009, Mr. Belsky served as Vice President, Finance, and Chief Accounting Officer of Cell Genesys, Inc., a biotechnology company acquired by BioSante Pharmaceuticals, Inc. Prior to 2006, Mr. Belsky served as Vice President, Global Visa Commerce at Visa Inc., Chief Financial Officer at Active Aero Group, Inc. and Chief Financial Officer at DataWave Systems Inc. Prior to these positions, he served for 15 years at Michigan National Corporation, a holding company for Michigan National Bank, which was acquired by BANA Holding Corporation, in positions of increasing responsibility, most recently as Senior Vice President, U.S. Payment Products and Services. Mr. Belsky started his career as an auditor with Coopers & Lybrand. Mr. Belsky received a B.S. in Accounting from Wayne State University and an M.B.A. from University of Michigan. He is a certified public accountant, a chartered global management accountant and a certified treasury professional.
Senior Vice President and Chief Business Officer
Mr. Knickerbocker has served as our Senior Vice President and Chief Business Officer since April 2012 and as a member of our board of directors since October 2013. From September 2009 to April 2012, he served as our Vice President, Business Development. From 2001 to September 2009, Mr. Knickerbocker served at Genentech, Inc. in positions of increasing responsibility most recently as Senior Director, Business Development from 2005 to September 2009. Prior to 2001, Mr. Knickerbocker served as Director of Commercial Development at ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, as Senior Manager, Corporate Development at Amgen Inc., a public biotechnology company and as a scientist at Bristol-Myers Squibb Company, a public biopharmaceutical company. Mr. Knickerbocker received an A.B. in biology from Washington University in St. Louis and an M.B.A. from the University of Michigan.
Senior Vice President, General Counsel and Secretary
Mr. Sarena has served as our Senior Vice President since January 2013, and as General Counsel and Secretary since December 2010. Mr. Sarena also served as Vice President from December 2010 to January 2013. From December 2008 to July 2010, Mr. Sarena served as Vice President, General Counsel and Secretary of Facet Biotech Corporation, a public biotechnology company that was spun off from PDL BioPharma, Inc. in December 2008 and was later acquired by Abbott Laboratories in April 2010. From April 2006 to December 2008, Mr. Sarena served at PDL BioPharma, Inc. in positions of increasing responsibility, most recently as Vice President, General Counsel and Secretary from June 2008 to December 2008. Prior to April 2006, Mr. Sarena served as an associate at Bingham McCutchen LLP where he represented public and private life science and high tech clients primarily in merger and acquisition transactions, corporate and securities law matters and equity financing transactions. Mr. Sarena received a B.S. in Finance from San Francisco State University and a J.D. from University of California, Berkeley.
Senior Vice President, Human Resources
Ms. Cesario has served as our Vice President, Human Resources, since August 2009. From 2001 to 2006, Ms. Cesario served as Vice President, Human Resources at Affymetrix, Inc. From 1997 to 2001, Ms. Cesario served as Vice President, Human Resources at Scios, Inc. Prior to 1997, Ms. Cesario served for 18 years in human resources positions of increasing scope and responsibility at Silicon Graphics, Inc., National Semiconductor Corporation, Syntex Corporation and Bank of America. Ms. Cesario received a B.S. in Psychology from Loyola University.
Brian Wong, M.D., Ph.D.
Senior Vice President, Research and Head of Immuno-Oncology
Dr. Wong has over 15 years of novel target, biomarker, and drug discovery experience in the biotechnology and pharmaceutical industry. Dr. Wong joined FivePrime in 2009, and has held positions of increasing responsibility, most recently as Vice President, Research and Head of Immuno-Oncology. Prior to FivePrime, Dr. Wong served as Director of Research in the Inflammation Disease Biology Area at Roche Palo Alto from 2005 to 2009. There he led the development of Roche's rheumatology discovery portfolio, consisting of ~20 biologics and small molecule programs in phases from discovery to early clinical development. From 2000 to 2005, Dr. Wong held various leadership roles at Rigel Pharmaceuticals, where he identified and developed clinical candidates to multiple novel targets for allergic, autoimmune, and respiratory disorders. Dr. Wong was trained as a Medical Scientist Training Program fellow, during which he received an M.D. from the Weill Cornell Medical College of Cornell University and a Ph.D. in Immunology from The Rockefeller University under Dr. Yongwon Choi, Ph.D., a Howard Hughes Medical Institute Investigator, and Nobel laureate Dr. Ralph Steinman, M.D. Dr. Wong received a B.A. in Chemistry and Biochemistry from Oberlin College and began his scientific career in the laboratory of Dr. Richard Scheller, Ph.D., a Howard Hughes Medical Institute Investigator at Stanford University.
Luis Borges, Ph.D.
Vice President, Immuno-Oncology Research
Dr. Borges has served as our Vice President, Immuno-Oncology Research, since July 2015. From February 2015 to July 2015 he served as our Executive Director, Immuno-Oncology Validation, and from May 2014 to February 2015 he served as our Senior Director, Translational Immunology. From 2002 to May 2014, Dr. Borges served in positions of increasing responsibility at Amgen Inc., most recently as Scientific Director, Therapeutic Innovation Unit. From 1996 to 2002, Dr. Borges served at Immunex Corporation initially as a Postdoctoral Scientist and later as a Staff Scientist. Immunex was acquired by Amgen in 2002. Dr. Borges received a B.S. from the University of Lisbon and a Ph.D. in Pathology from University of Washington.
Robert Sikorski, M.D., Ph.D.
Vice President, Global Clinical Development
Dr. Sikorski has served as our Vice President of Global Clinical Development since September, 2014. From December, 2010 to September, 2014 he was Senior Director, Global Oncology Research and Development at Medimmune, leading the development of a portfolio of oncology therapeutics with a focus on immune-mediated therapies. Prior to joining Medimmune, he was Director, Global Oncology Research and Development at Amgen, where he led the development of several oncology drug candidates. Here, he played a key role in achieving marketing approval for Vectibix based on a first-in-class biomarker. In earlier positions, he served as a medical affairs consultant to Genzyme and as Chief Technology Officer at the biomedical data acquisition and analytics firm, Mednav. Dr. Sikorski received his M.D. and Ph.D. from The Johns Hopkins University School of Medicine through a Medical Scientist Training Program scholarship. He completed his residency at Massachusetts General Hospital and an oncology fellowship at The Johns Hopkins Oncology Center, and is board certified in both oncology and internal medicine. Dr. Sikorski began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate, Harold Varmus.